Ocriplasmin for Treatment of Vitreomacular Traction and Macular Hole A Systematic Literature Review and Individual Participant Data Meta-Analysis of Randomized, Controlled, Double-Masked Trials.

[1]  F. Folgar,et al.  Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis. , 2019, Ophthalmology. Retina.

[2]  R. Sergott,et al.  EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT , 2017, Retina.

[3]  L. Duchateau,et al.  Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study. , 2017, Investigative ophthalmology & visual science.

[4]  Timothy L. Jackson,et al.  Ocriplasmin for symptomatic vitreomacular adhesion. , 2017, The Cochrane database of systematic reviews.

[5]  Jennifer I. Lim,et al.  Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion. , 2017, Ophthalmology. Retina.

[6]  L. Duchateau,et al.  Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study. , 2017, Investigative ophthalmology & visual science.

[7]  L. Duchateau,et al.  Visual function response to ocriplasmin for the treatment of vitreomacular traction: results from the oasis study , 2016 .

[8]  L. Feiner,et al.  Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial. , 2016, Ophthalmology.

[9]  C. Regillo,et al.  Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin. , 2016, Ophthalmic surgery, lasers & imaging retina.

[10]  P. Stalmans.  A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit) , 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.

[11]  J. Folk,et al.  Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern(®) Guidelines. , 2016, Ophthalmology.

[12]  P. Kaiser,et al.  Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. , 2015, JAMA ophthalmology.

[13]  C. Regillo,et al.  Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials. , 2015, American journal of ophthalmology.

[14]  Mike Clarke,et al.  Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use , 2015, PLoS medicine.

[15]  A. Kampik,et al.  ASSOCIATION BETWEEN ANATOMICAL RESOLUTION AND FUNCTIONAL OUTCOMES IN THE MIVI-TRUST STUDIES USING OCRIPLASMIN TO TREAT SYMPTOMATIC VITREOMACULAR ADHESION/VITREOMACULAR TRACTION, INCLUDING WHEN ASSOCIATED WITH MACULAR HOLE , 2015, Retina.

[16]  P. Kaiser,et al.  SAFETY PROFILE OF OCRIPLASMIN FOR THE PHARMACOLOGIC TREATMENT OF SYMPTOMATIC VITREOMACULAR ADHESION/TRACTION , 2015, Retina.

[17]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.

[18]  A. Kampik,et al.  Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. , 2015, Ophthalmology.

[19]  G. Ruxton,et al.  Review of alternative approaches to calculation of a confidence interval for the odds ratio of a 2 × 2 contingency table , 2013 .

[20]  A. Kampik,et al.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. , 2012, The New England journal of medicine.

[21]  C. Delaey,et al.  INTRAVITREAL INJECTION OF MICROPLASMIN FOR TREATMENT OF VITREOMACULAR ADHESION: Results of a Prospective, Randomized, Sham-Controlled Phase II Trial (The MIVI-IIT Trial) , 2010, Retina.

[22]  Mark W. Johnson.  Posterior vitreous detachment: evolution and complications of its early stages. , 2010, American journal of ophthalmology.

[23]  J. Sebag.  Vitreous: the resplendent enigma , 2009, British Journal of Ophthalmology.

[24]  D. Charteris,et al.  The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations , 2009, British Journal of Ophthalmology.

[25]  Y. Shih,et al.  Changes of the ocular refraction among freshmen in National Taiwan University between 1988 and 2005 , 2009, Eye.

[26]  C K Hsiao,et al.  Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. , 2004, Annals of the Academy of Medicine, Singapore.

[27]  L. Stewart,et al.  To IPD or not to IPD? , 2002, Evaluation & the health professions.

[28]  Risk factors for branch retinal vein occlusion. The Eye Disease Case-control Study Group. , 1993, American journal of ophthalmology.

[29]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.